Welcome to the MDI website. Content and updating of information is ongoing on our website, therefore if you cannot find what you are looking for please contact us.

Vice-Chairperson – Róisin Glynn

Roisin Glynn

Roisin Glynn

Name
Ms. Roisin Glynn

Current Position on Board
Vice Chairperson

Current Position/Job Title
Senior Business Manager at AIB

I am currently Business Manager to the Managing Director of Homes & Consumer Banking in AIB, ensuring delivery on strategic projects in the Homes and Consumer business. Homes is responsible for meeting the Homes needs of all our customers across AIB, EBS and Haven brands.

Previous Position/Job Title
•            
Senior Business Manager to MD Homes & Consumer Banking
•             Head of Social Media at AIB
•             Digital Brand Manager at AIB
•             Marketing Executive at Davy

Current Membership of any Boards/Committees
•            
MDI Board

Previous Membership of any Boards/Committees
•            
MDI Board 23/09/2019 – 12/09/2020 (AGM)

Why I want to be on the Board of Muscular Dystrophy Ireland:
I believe that MDI provides a vitally important service for people with muscular dystrophy and their families. As someone who has a family member living with MD, I see the value and importance of MDI in supporting its member base and promoting independent living through a wide range of services.

What I bring to the Board of Muscular Dystrophy Ireland as a Director:
I have worked in AIB for a number of years in strategic roles and have extensive experience working in Marketing but also have worked closely with HR, finance and our strategy teams, all these things would be beneficial to the MDI board. As well as my professional experience I am passionate about the work that MDI do having grown up with my sister who suffers from MD and I am keen to contribute in whatever way I can to ensuring the continued success of the organisation.

How I can help Muscular Dystrophy Ireland achieve its mission:
I can help MDI to deliver its mission by working with the board of the organisation with the management team to ensure MDI has a clear vision and strategy. I will ensure to live by the values that MDI believes in and dedicate time and energy to the board ensuring I carry out my duties and that the correct governance structures are in place to ensure the organisation is meeting member needs.

1. Muscular Dystrophies

  • Becker muscular dystrophy
  • Duchenne muscular dystrophy
  • Manifesting carrier of Duchenne
  • Congenital muscular dystrophy - General
  • • MDC1A (merosin-deficient congenital muscular dystrophy)
  • • Rigid spine syndrome (RSS)
  • • Ullrich congenital muscular dystrophies
  • • Bethlem myopathy
  • Emery-Dreifuss muscular dystrophy

2. Myotonic Disorders

  • Congenital Myotonic Dystrophy
  • Myotonia
  • Myotonic Dystrophy

3. Congenital Myopathies

  • Central Core Myopathy
  • Minicore (Multicore) myopathy
  • Myotubular or Centronuclear myopathy
  • Nemaline myopathy

4. Mitochondrial Myopathies

  • Mitochondrial Myopathies

5. Metabolic Disorders

  • Metabolic disorders (general)
  • McArdle’s Disease
  • Pompe’s Disease

6. Periodic Paralyses

  • Periodic Paralyses

7. Autoimmune Myositides

  • Polymyositis, Dermatomyositis and Sarcoid myopathy
  • Juvenile dermatomyositis
  • Inclusion body myositis

8. Spinal Muscular Atrophies

  • Severe (Type I)
  • Intermediate (Type II)
  • Mild (Type III)
  • Adult spinal muscular atrophy

9. Hereditary Motor and Sensory Neuropathies

  • (Also known as Charcot-Marie-Tooth or Peroneal muscular atrophy)

10. Disorders of the Neuromuscular Junction

  • Congenital myasthenic syndromes
  • Myasthenia Gravis

11. Friedreich’s Ataxia

  • Facioscapulohumeral muscular dystrophy
  • Limb-girdle types of muscular dystrophy (LGMD) - General
  • • LGMD 1B (also known as Laminopathy)
  • • LGMD 1C (also known as Caveolinopathy)
  • • LGMD 2A (also known as Calpainopathy)
  • • LGMD 2B (also known as Dysferlinopathy)
  • • LGMD 2I
  • Ocular myopathies including ocularopharangeal muscular dystrophy

12. Other (Please Specify)

13. Unspecified